Clinuvel Pharmaceuticals Limited (FRA:UR9)

Market Cap	351.36M
Revenue (ttm)	53.04M
Net Income (ttm)	20.19M
Shares Out	n/a
EPS (ttm)	0.40
PE Ratio	17.40
Forward PE	16.64
Dividend	0.03 (0.42%)
Ex-Dividend Date	Sep 4, 2025

Volume	n/a
Average Volume	227
Open	6.90
Previous Close	6.80
Day's Range	6.90 - 6.90
52-Week Range	4.80 - 7.93
Beta	n/a
RSI	61.82
Earnings Date	Nov 27, 2025

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 16
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UR9

Financial Performance

In 2025, Clinuvel Pharmaceuticals's revenue was 95.02 million, an increase of 7.76% compared to the previous year's 88.18 million. Earnings were 36.17 million, an increase of 1.50%.

Financial numbers in AUD